| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.66 [0.54, 0.80] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.68 [0.57, 0.81] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.61 [0.53, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.58 [0.50, 0.68] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 3.70 [2.71, 5.06] | | > 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| STRAE (any grade) | 0.65 [0.46, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 1.36 [0.98, 1.90] | | < 1 | | 25% | 2 studies (2/-) | 3.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.83 [0.61, 1.13] | | < 1 | | 0% | 2 studies (2/-) | 88.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.37 [0.11, 17.90] | | < 1 | | 0% | 2 studies (2/-) | 40.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.97 [0.60, 1.60] | | < 1 | | 25% | 2 studies (2/-) | 54.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 1.16 [0.16, 8.29] | | < 1 | | 0% | 2 studies (2/-) | 44.1 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Chills TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.27 [0.14, 0.54] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.85 [0.06, 55.43] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.66 [0.29, 1.54] | | < 1 | | 0% | 2 studies (2/-) | 83.0 % | some concern | not evaluable | moderate | non important | - |
| Dry skin TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.64 [0.17, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 74.9 % | some concern | not evaluable | moderate | non important | - |
| Headache TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.66 [0.77, 17.46] | | < 1 | | 0% | 2 studies (2/-) | 5.2 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.37 [0.11, 17.90] | | < 1 | | 0% | 2 studies (2/-) | 40.6 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.8 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Uveitis TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 1.37 [0.11, 17.90] | | < 1 | | 0% | 2 studies (2/-) | 40.6 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
